Teleukin is a fully-human vascular targeting immunocytokine, currently being tested in Phase II clinical trials in patients with cancer in combination both with paclitaxel or with doxorubicin.

The rationale for the development of this product relies on the fact that recombinant interleukin-2 is an approved biopharmaceutical (“Proleukin TM”; Novartis) and that the fusion protein, consisting of the human vascular targeting antibody F16 and of human interleukin-2, has demonstrated a striking superiority compared to non-targeted interleukin-2 in animal models of cancer.

This product is particularly indicated for breast, lung, melanoma and angiosarcoma, where it has shown superior immunohistochemical staining performance, compared to L19-IL2.

SELECTED REFERENCES
De Braud et al. (2010) J Clin. Oncol.,  28, e13017;
Marlind et al. (2008) Clin. Cancer Res.,14, 6515-24;
Brack et al. (2006) Clin. Cancer Res., 12, 3200-3208.

<< Pipeline